83
55
Growth Score
-7 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
563166
A pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach.
- Wayne Cheney: President, Chief Scientific Officer and Founder
- Elaine Allison: Co-Founder, CEO
About the Company
They are a pre-clinical stage biotech company developing innovative antibody immunotherapies for cancer using a novel “Interceptor” approach. Our antibodies bind only to specific immunosuppressive proteins that are released from cancer cells (soluble ligands), and not to the cell surface-bound versions. This treatment is predicted to be effective
towards multiple types of cancers and has safety built into the design of the drug, thereby minimizing the likelihood of unwanted side effects. Our current studies have demonstrated efficacy in repeated prostate cancer models in mice.
